SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-047488
Filing Date
2021-09-09
Accepted
2021-09-09 16:30:58
Documents
13
Period of Report
2021-09-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-8k_20210909.htm   iXBRL 8-K 41591
2 EX-99.1 kalv-ex991_6.htm EX-99.1 384683
  Complete submission text file 0001564590-21-047488.txt   571212

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kalv-20210909.xsd EX-101.SCH 5685
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20210909_lab.xml EX-101.LAB 19339
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20210909_pre.xml EX-101.PRE 11490
6 EXTRACTED XBRL INSTANCE DOCUMENT kalv-8k_20210909_htm.xml XML 3560
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 211244754
SIC: 2834 Pharmaceutical Preparations